Last reviewed · How we verify

NCT05355714

High Intensity Ultrasound for the Treatment of Upper Inner Arm Skin Laxity

Status unknown NA Last updated 2 May 2022
What this trial tests

NA trial testing Sofwave in Skin Laxity in 15 participants. Status unknown.

Timeline
14 April 2022
Primary endpoint
30 April 2023
1 October 2023

Quick facts

Lead sponsorGoldman, Butterwick, Fitzpatrick and Groff
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment15
Start date14 April 2022
Primary completion30 April 2023
Estimated completion1 October 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Goldman, Butterwick, Fitzpatrick and Groff — full company profile →

Who can join

Adults 35 to 70, any sex, with Skin Laxity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Upper inner arms of enrolled subjects will be randomized to two (2) treatment groups: Sofwave and Ultherapy, with subjects receiving treatment with one device on their right side and the other on their left.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sofwave

Trials testing the same drug.

Other recruiting trials for Skin Laxity

Currently open trials in the same condition.

Other Goldman, Butterwick, Fitzpatrick and Groff trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05355714.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing